ClinicalTrials.Veeva

Menu
E

Exalt Clinical Research, Inc. | Chula Vista, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

ESK-001
AD109
Atomoxetine
E2086
Aroxybutynin
IHL-42X

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 7 total trials

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Enrolling
Plaque Psoriasis
Drug: Placebo
Drug: Apremilast

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

The goal of this randomised, double-blind phase II/III clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive...

Active, not recruiting
Obstructive Sleep Apnea
Drug: Acetazolamide
Drug: IHL-42X Low Dose

Trial sponsors

A
Apnimed logo
Eisai logo
I
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems